冠昊生物
(300238)
| 流通市值：27.20亿 | | | 总市值：28.18亿 |
| 流通股本：2.65亿 | | | 总股本：2.75亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 250,582,625.52 | 174,516,375.45 | 93,444,027.57 | 387,749,767.9 |
| 营业收入 | 250,582,625.52 | 174,516,375.45 | 93,444,027.57 | 387,749,767.9 |
| 二、营业总成本 | 237,418,751.81 | 161,974,132.06 | 83,859,027.31 | 358,622,829.07 |
| 营业成本 | 61,677,276.74 | 41,615,833.26 | 21,826,801.12 | 88,670,267.74 |
| 税金及附加 | 5,408,272.23 | 3,424,736.66 | 1,817,625.02 | 7,457,600.58 |
| 销售费用 | 100,145,122.5 | 68,826,465.38 | 37,291,654.14 | 160,935,392.93 |
| 管理费用 | 43,821,221.72 | 30,870,171.42 | 14,177,324.89 | 57,210,995.98 |
| 研发费用 | 24,337,063.88 | 16,015,191.4 | 8,052,164.27 | 40,965,725.76 |
| 财务费用 | 2,029,794.74 | 1,221,733.94 | 693,457.87 | 3,382,846.08 |
| 其中:利息费用 | 2,596,752.98 | 1,666,148.25 | 942,466.15 | 4,035,969.72 |
| 其中:利息收入 | 341,814.93 | 265,772.48 | 159,041.56 | 663,463.45 |
| 三、其他经营收益 | | | | |
| 加:投资收益 | -153,040.41 | -153,040.41 | -153,040.41 | 1,894,614.62 |
| 资产处置收益 | 88,775.14 | 88,775.14 | 88,241.47 | -5,119.4 |
| 资产减值损失(新) | -364,449.55 | -285,187.29 | 7,760.08 | -1,901,987.23 |
| 信用减值损失(新) | -934,235.15 | -1,219,768.96 | -254,396.99 | -1,284,799.19 |
| 其他收益 | 2,554,959.62 | 2,167,158.85 | 1,427,731.84 | 2,623,865.52 |
| 四、营业利润 | 14,355,883.36 | 13,140,180.72 | 10,701,296.25 | 30,453,513.15 |
| 加:营业外收入 | 541,736.11 | 341,735.66 | 331,801.64 | 900,054.95 |
| 减:营业外支出 | -217,354.32 | -263,975.13 | 519,430.24 | 4,073,006.27 |
| 五、利润总额 | 15,114,973.79 | 13,745,891.51 | 10,513,667.65 | 27,280,561.83 |
| 减:所得税费用 | 8,344,036.51 | 6,092,162.52 | 3,311,199.98 | 12,493,291.79 |
| 六、净利润 | 6,770,937.28 | 7,653,728.99 | 7,202,467.67 | 14,787,270.04 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 6,770,937.28 | 7,653,728.99 | 7,202,467.67 | 14,787,269.94 |
| 终止经营净利润 | - | - | - | 0.1 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 15,945,054.57 | 13,239,784.88 | 10,162,275.45 | 24,346,028.28 |
| 少数股东损益 | -9,174,117.29 | -5,586,055.89 | -2,959,807.78 | -9,558,758.24 |
| 扣除非经常损益后的净利润 | 13,659,357.64 | 10,423,780.18 | 9,242,718.55 | 26,311,919.29 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.06 | 0.05 | 0.04 | 0.09 |
| (二)稀释每股收益 | 0.06 | 0.05 | 0.04 | 0.09 |
| 八、其他综合收益 | -249,353.6 | -191,767.96 | -112,033.94 | -125,555.44 |
| 归属于母公司股东的其他综合收益 | -249,353.6 | -191,767.96 | -112,033.94 | -125,555.44 |
| 九、综合收益总额 | 6,521,583.68 | 7,461,961.03 | 7,090,433.73 | 14,661,714.6 |
| 归属于母公司股东的综合收益总额 | 15,695,700.97 | 13,048,016.92 | 10,050,241.51 | 24,220,472.84 |
| 归属于少数股东的综合收益总额 | -9,174,117.29 | -5,586,055.89 | -2,959,807.78 | -9,558,758.24 |
| 公告日期 | 2026-10-29 | 2026-08-29 | 2026-04-29 | 2026-03-26 |
| 审计意见(境内) | | | | 标准无保留意见 |